<DOC>
	<DOC>NCT00975533</DOC>
	<brief_summary>This study aims to analyze the pre- and post-operative clinical, hormonal and biochemical changes in moderately obese type 2 diabetic patients who are sub-optimally controlled on at least 2 anti-diabetic agents. Study participants will either receive implantation of the gastric contraction modulator or conventional treatment with insulin therapy.</brief_summary>
	<brief_title>Gastric Modulator (TANTALUSÂ® System) Versus Insulin Treatment in Obese Type 2 Diabetic Patients - a Randomized Control Trial</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Able to provide written informed consent Adult patients aged between 18 and 60 years (inclusive) Male or female of Chinese ethnicity Type 2 diabetes mellitus with disease duration of greater than 2 and less than 10 years severe obesity, includes BMI 25 to 27.5 kg/m and central obesity defined by waist circumference greater than 90 cm in women and greater than 95 in men, or BMI greater than 27.5 to less than 35 kg/m HbA1c greater than or equals to 7.5% but less than 10% despite treated with maximum dose or maximally tolerated dose of 2 antidiabetic drugs (OAD) with good drug compliance On antiobesity drugs On insulin treatment at the time of the recruitment On glitazone or incretins (dipeptidyl peptidase4 inhibitor or glucagonslike peptide1) treatment On any implantable device including cardiac pacing Anticipated to have MRI examinations Fasting Cpeptide level less than 0.5g/L Renal impairment (defined as serum creatinine greater than 150mol/L and/or estimated glomerular filtration rate less than 60 mL/min/1.73m) Significant liver impairment (ALT more than 3 times upper limit of normal range) Active malignant disease. Patients with malignant disease who have been diseasefree for at least 5 years are eligible Active infection Active and uncontrolled thyroid diseases Childbearing age female patients without reliable contraceptive methods Life expectancy less than 12 months Administration of another investigational drugs or procedures within 4 weeks before screening Any medical illness or condition as judged by the investigators as ineligible to participate the study Special population, e.g. prisoner, mentally disabled, investigators' student or employees</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>type 2 diabetes mellitus</keyword>
	<keyword>obesity</keyword>
</DOC>